Justin Striblen, MD
Internal Medicine · Las Vegas, NVNPI 1962563569
Payments from drug & device makers
Across 329 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$778
- Boehringer Ingelheim$654
- Novo Nordisk$437
- Pfizer$416
- Astellas Pharma US Inc$384
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,59798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $1,889 |
| AbbVie | 48 | $778 |
| Boehringer Ingelheim | 49 | $654 |
| Novo Nordisk | 21 | $437 |
| Pfizer | 34 | $416 |
| Astellas Pharma US Inc | 16 | $384 |
| Abbott | 21 | $343 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $158 |
| Novartis | 5 | $77 |
| Exact Sciences | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Merck | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Eisai Inc. | 2 | $29 |
| Bayer | 2 | $28 |
| Amgen | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| IBSA Pharma Inc. | 2 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| GSK | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $14 |
| Viiv Healthcare Company | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$479
- BYDUREON$317
- SYMBICORT$317
- BREZTRI$162
- BREZTRI AEROSPHERE$152
How this compares
$5,696 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 107 | $142,671 |
| EliquisApixaban | 165 | $135,850 |
| JardianceEmpagliflozin | 48 | $67,901 |
| JanuviaSitagliptin Phosphate | 45 | $63,648 |
| OzempicSemaglutide | 46 | $47,030 |
| XareltoRivaroxaban | 67 | $38,801 |
| RybelsusSemaglutide | 16 | $34,159 |
| NuplazidPimavanserin Tartrate | 21 | $28,529 |
| MounjaroTirzepatide | 17 | $24,858 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $19,508 |
| TradjentaLinagliptin | 18 | $17,991 |
| LinzessLinaclotide | 13 | $16,149 |
| MyrbetriqMirabegron | 31 | $13,591 |
| BelsomraSuvorexant | 19 | $12,072 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $10,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,889 | $142,671107 claims |
| PfizerEliquis | $416 | $135,850165 claims |
| Boehringer IngelheimJardiance, Tradjenta | $654 | $85,89266 claims |
| Novo NordiskOzempic, Rybelsus | $437 | $81,18962 claims |
| MerckJanuvia, Belsomra | $44 | $75,71964 claims |
| Lilly USA, LLCMounjaro | $13 | $24,85817 claims |
| GSKBreo Ellipta, Arexvy | $18 | $23,38533 claims |
| AbbVieLinzess, Synthroid | $778 | $18,58876 claims |
| Astellas Pharma US IncMyrbetriq | $384 | $13,59131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Vrijendra HoonLas Vegas$1.8M
- Robby Ann QuintosLas Vegas$1.4M
- Kent SwaineLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.